Abstract and Introduction
In the HAART era, clinicians are faced with the challenge of treating an aging HIV-infected population increasingly affected by severe comorbidities, which may compromise the tolerability of antiretroviral regimens. In this special population, it is imperative for physicians to carefully tailor antiretroviral treatment in order not to worsen patients' underlying clinical conditions and to achieve both tolerability and immune–virologic efficacy. This article aims to explore the impact of standard HAART regimens on the different noninfectious HIV-related comorbidities: metabolic, cardiovascular, bone and renal diseases, in order to provide tools to fit the most appropriate antiretroviral combination according to individual clinical conditions. Clinical experience with alternative antiretroviral strategies, avoiding nucleoside reverse transcriptase inhibitor toxicities and involving new antiretroviral classes, will be reviewed to obtain an overview on future perspectives.
HIV Ther. 2010;4(5):553-565. © 2010
Future Medicine Ltd.
Cite this: Noninfectious HIV-related Comorbidities and HAART Toxicities: Choosing Alternative Antiretroviral Strategies - Medscape - Sep 01, 2010.